1. Boulay A, Lane HA (2007) The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res Fortschr Krebsforsch Prog Dans Rech Sur Cancer 172:99–124 .
https://link.springer.com/chapter/10.1007%2F978-3-540-31209-3_7?LI=true
. Accessed 7 July 2018
2. Wong M (2013) Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J 36(2):40–50
3. French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Lond Engl 388(10056):2153–2163
4. Jóźwiak S, Kotulska K, Berkowitz N, Brechenmacher T, Franz DN (2016) Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial. J Pediatr 172(151–155):e1
5. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E et al (2016) Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 31(1):111–119